Outlining the Phase III Approval of ImmunoGen’s ELAHERE, Lessons Learned & Next Steps

Time: 8:30 am
day: Conference Day One


  • Exploring the rollercoaster journey of ImmunoGen’s Mirvetuximab Soravtansine, which targets folate receptor alpha
  • Emphasizing the importance of designing a clinical trial to enrol the right patients and utilizing biomarker strategies
  • Discussing the next steps for ImmunoGen following this ground-breaking approval